#AS­CO21: As­traZeneca takes a swing at J&J and Ab­b­Vie's Im­bru­vi­ca with long-term da­ta from head-to-head tri­al

A year and a half af­ter get­ting its next-gen BTK in­hibitor ap­proved in chron­ic lym­pho­cyt­ic leukemia (CLL), As­traZeneca is back with long-term da­ta that sug­gest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.